Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
24.23
-0.08 (-0.33%)
Dec 23, 2025, 4:00 PM EST - Market closed
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts that cover Catalyst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $32.6, which forecasts a 34.54% increase in the stock price over the next year. The lowest target is $30 and the highest is $35.
Price Target: $32.6 (+34.54%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +36.19% | Nov 7, 2025 |
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +32.07% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +44.45% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $33 | Buy | Reiterates | $33 | +36.19% | Feb 27, 2025 |
| Baird | Baird | Buy Initiates $28 | Buy | Initiates | $28 | +15.56% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
589.43M
from 491.73M
Increased by 19.87%
Revenue Next Year
631.91M
from 589.43M
Increased by 7.21%
EPS This Year
1.57
from 1.31
Increased by 19.91%
EPS Next Year
2.03
from 1.57
Increased by 29.22%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 615.3M | 665.4M | ||||
| Avg | 589.4M | 631.9M | ||||
| Low | 561.1M | 583.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.1% | 12.9% | ||||
| Avg | 19.9% | 7.2% | ||||
| Low | 14.1% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.70 | 2.84 | |||
| Avg | 1.57 | 2.03 | |||
| Low | 1.38 | 1.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.8% | 80.5% | |||
| Avg | 19.9% | 29.2% | |||
| Low | 5.5% | -3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.